Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

The University of Kansas will have what it says is the smallest four-year medical education site in the country when eight students begin taking classes on Monday on a satellite campus in Salina, Kansas. The move is in response to a shortage of rural doctors in the United States. “By training physicians in a nonmetropolitan area, we are showing young medical students that life can be good, and practice can be stimulating, outside of the big city,” said Dr. William Cathcart-Rake, the physician who directs the University of Kansas School of Medicine-Salina. Students will get some course work via tele-video and podcasts from the school’s other campuses, but they will also train through visits to doctors’ offices in small communities and at the hospital in Salina, school officials said. “It’s a bold and innovative move,” said Dr. Roland Goertz, president of the American Academy of Family Physicians. He said students at rural clinics will be exposed to a potential medical career they wouldn’t see in urban hospital settings. Cathcart-Rake said six of the eight students being taught at Salina, as part of their scholarships, have committed to practicing in a rural area. Seven of the eight students are from rural areas to begin with, he said. “They see the value of living in wide open spaces and going back to where their friends are,” Cathcart-Rake said. Attending medical school in a place such as Salina reduces chances they will change their minds, which could happen if they went to a big-city school, he said. Salina, with 46,000 residents, is about 175 miles west of the Kansas City metropolitan region where the university’s main medical school is located. Small-town America has become increasingly under-served by doctors. About 21 percent of U.S. residents live in rural regions but only about 10 percent of physicians practice there, according to data cited by the family physicians group. In Kansas, 12 counties don’t have a full-time doctor at all, said Barbara Atkinson, executive dean of the University of Kansas School of Medicine. Several factors are often cited for a shortage of rural doctors. Rural doctors tend to be paid less, partly because they are more likely to treat patients on Medicare and Medicaid, which reimburses at rates below standard insurance. General practitioners make up the largest share of rural doctors, but until recent years fewer medical students were going into general medicine, putting a strain on rural care. Older doctors who practice in small towns and retire are sometimes not replaced because younger doctors may prefer the greater cultural amenities urban regions tend to offer. Recent changes in federal healthcare laws are intended to make rural practice more acceptable to doctors. Doctors who practice in certain underserved areas will get bonuses beyond the 10 percent boost in Medicare reimbursements they were already receiving, Goertz said. He said another reason why there are fewer rural doctors is that the large majority of medical students come from urban areas, where medical schools are usually located, making them less like to consider rural medicine. “You tend to gravitate to where you grew up,” Goertz said. Cathcart-Rake is optimistic that the Salina medical school will be a success and that in future years admissions may grow from eight to 12 students.
Rural doctor shortage prompts opening of medical school.

"The article doesn't mention costs of angioplasty or costs of medications, which presumably must be taken for the rest of one's life. The article does mention that angioplasty is expensive, but does not provide real numbers or comparisons. The story provides absolute numbers of the primary endpoint over a 4-year period — ""17 percent of those given angioplasty and drugs and nearly 16 percent of those given drugs alone had either died, suffered another heart attack or developed heart failure — results considered to be statistically the same."" The story states that there was a worrisome trend toward more heart attacks in people who received late angioplasty compared to those who received just medications, although the story also tells readers that this could have been a statistical fluke or due to chance. However, other harms of the procedure were not discussed, including risks of the procedure itself, including bleeding, infection, or emotional distress/anxiety. The article also does not discuss risks of the alternative, e.g. medications, which have side effects, costs, or inconvenience. But, the story does discuss the main harm found in the study, e.g. a trend toward increased heart attacks. The research is important because it is a randomized controlled trial and the first such trial to be conducted for the clinical situation of late angioplasty in people with few to no symptoms after their heart attack. The story tells readers that enrollment of patients was delayed because ""doctors were unwilling to risk randomly assigning patients to drug treatment alone,"" indirectly stating that the study was a randomized trial. While an astute reader could probably pick up that this was a randomized trial, this fact could have been clearer. In addition, there is little context around this being the first randomized trial for this clinical situation (as opposed to retrospective observational studies), although the story does tell readers that the results were surprising and that they could change guidelines. The story appropriately describes a heart attack, and more importantly, reinforces that early opening of the artery to restore blood flow to the heart after heart attack is still beneficial and that these results don't apply to that population or indeed the majority of people receiving angioplasties. No obvious disease mongering. The article provides an independent source of information from the chairman of the American Heart Association program committee that reviewed the research. The story also provides information from the director of the National, Heart, Lung, and Blood Institute, but tells readers that this organization largely funded the research, therefore disclosing potential conflicts of interest. The story tells readers that the alternative that was tested in the latest research was medications, including those to lower blood pressure and cholesterol, aspirin, and anti-clotting drugs. The story could have mentioned beta-blockers specifically, since the protective effect of drug treatment may come from this family of drugs, although this is not yet proven. And the story could have been clearer about the course of treatment, e.g. that these medications are generally taken for the rest of one's life. The story tells readers that the usual treatment for people suffering a heart attack is angioplasty, even for a subset of people who weren't treated right away (the study population)/  The article also tells readers that the tendency to perform angioplasty electively (3 to 28 days after the event) was so strong, that recruitment to the study was prolonged in order to find enough patients (and their doctors) willing to participate in the study. It's widely understood that angioplasty and standard drug therapy after heart attack are not new. The article provides independent sources of information not included in the press release."
Study says late angioplasty futile

General David Rodriguez, head of U.S. forces in Africa, said three mobile labs had deployed to Liberia and four more were being sought to run tests that would distinguish between people infected with Ebola and those who have diseases with similar symptoms, such as malaria. Each lab would be staffed by a team of three to four experts trained to operate in the worst chemical, biological and nuclear environments, Rodriguez told reporters at a Pentagon briefing. The teams operate in full protective clothing. Ebola, which can cause fever, vomiting and diarrhea, spreads through contact with bodily fluids such as blood or saliva. The U.S. military is ramping up its response to the Ebola outbreak in West Africa, where it has already killed more than 3,400 people in Liberia, Sierra Leone and Guinea. Concern is growing that the virus could spread to other parts of the world. The United States has 348 military personnel in Liberia and Senegal working on combating the spread of Ebola. Rodriguez has been authorized to send some 3,900 troops if needed. He said at this point he expected the effort to last a year and did not think more troops would be necessary. “We’re going to stay as long as we’re needed, but not longer,” said Rodriguez, who estimated the cost of the military operation at $750 million for the next six months. Many of the military personnel due to go to Liberia in the coming months are construction workers who will build up to 17 100-bed Ebola treatment facilities. Rodriguez said health officials estimated at least 70 percent of those diagnosed with the virus need to be in treatment facilities in order to slow the spread of the disease. Assistant Defense Secretary Andy Weber, who is responsible for nuclear, chemical and biological defense programs, said the Pentagon was working with international partners to ensure there are more beds than patients, aiming to contain the spread by isolating the patients. “If you’ve seen the modeling from CDC (Centers for Disease Control and Prevention), it’s on a fast rise. But we can turn it. We know what to do,” said Weber, who is leaving the Defense Department to become the deputy to the State Department’s Ebola Coordinator, Ambassador Nancy Powell. “Over half the people infected with Ebola can survive if they have just basic medical support,” he said. “So we can get ahead of this, but right now we’re playing catch-up because it really started to spread at an exponential rate in August.”  Weber said the U.S. departments of Defense and Health and Human Services had been primary investors in the search for drugs, vaccines and diagnostic tools to counter the Ebola virus, including the promising experimental drug ZMapp produced by Mapp Biopharmaceutical. “Ebola has always been on the threat list of agents that we’re concerned about,” he said, noting that rare diseases like Ebola are “not a commercial market so big pharma doesn’t have an interest in pursuing these, which is why the government involvement is so important.”

U.S. military specialists in Liberia to conduct Ebola testing: general.